37 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
12 May 23
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:35am
, compared to $6.7 million at December 31, 2022, an increase of $1.5 million.
R&D Expenses: Research and development expenses for the first quarter … of 2023 were $1.2 million, compared to $1.8 million for the first quarter of 2022.
R&D – Licenses Acquired Expenses: Research and development – licenses
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
14 Aug 20
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
8:30am
Following Abdominoplasty: A Three-Arm Randomized Placebo- and Active-Controlled Trial” was published in Drugs in R&D and can be accessed here … -to-date.
R&D Expenses: Research and development expenses for the second quarter of 2020 were $1.2 million, compared to $6.4 million in the second
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
30 Mar 20
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
9:01am
of December 31, 2019, our cash and cash equivalents totaled $8.7 million, compared to $2.7 million at December 31, 2018, an increase of $6.0 million.
R&D Expenses:Research … was primarily attributable to the completion of our abdominoplasty study as well as NDA submission costs.
R&D Expenses – Licenses Acquired:Research
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
14 Nov 18
Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
4:31pm
attributable to the continued Phase 3 development of IV tramadol.
R&D Expenses:Research and development expenses for the three months ended September 30, 2018
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
13 May 19
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
9:00am
closing of the agreement between InvaGen and Avenue.
R&D Expenses:Research and development expenses for the three months ended March 31, 2019, were $10.2
8-K
EX-99.1
96tij64yqwa2fdl 3f
4 Nov 19
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
9:00am
8-K
EX-99.1
cy1a7m3k
14 Aug 19
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
12:00am
8-K
EX-99.1
gd07fi8wf2gpfc
11 May 20
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
9:00am
8-K
EX-99.1
jfvmp64 24l9srvdv4
14 Aug 18
Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
9:00am
8-K
EX-99.1
x2bhej466cc8ith90urs
12 Mar 19
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights
9:16am
8-K
EX-99.1
v0nnx
3 May 18
Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
8:00am
8-K
EX-99.1
ep5umf
10 Nov 22
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
4:29pm
8-K
EX-99.1
78mdtsbv8fwikv89
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
8-K
EX-99.1
o1nmzv 9a94n1
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
8-K
EX-99.1
0yl0o 2ya
30 Mar 23
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
4:07pm
8-K
EX-99.1
4xxyz46zuu5cpl9me4
10 Aug 23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:20pm
DEF 14A
g5di02owlhjv y5w
30 Apr 18
Definitive proxy
7:02am